Reporting of comparative effectiveness observational studies must follow the STROBE guidelines
Authors should prepare a statistical analysis plan in advance
To provide a more complete picture of effectiveness, several outcomes across multiple health domains should be compared
Lost to follow-up from the study sample must be reported by the exposure of interest
The proportion of patients who stop and/or change therapy over time, as well as the reasons for treatment discontinuation must be reported
Covariates should be chosen based on subject matter knowledge and model selection should be justified
The study baseline should be at treatment initiation and a description of how covariate measurements relate to baseline should be included
The analysis should be based on all patients starting a treatment and not limited to patients remaining on treatment at a certain time point
When treatment discontinuation occurs before the time of outcome assessment, this attrition should be taken into account in the analysis.
Sensitivity analyses should be undertaken to explore the influence of assumptions related to missingness, particularly in case of attrition